Fate Therapeutics (FATE) News Today → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free FATE Stock Alerts $4.15 +0.07 (+1.72%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 6:26 AM | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Price Target Cut to $6.00May 14 at 4:34 AM | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Price Target Cut to $4.00 by Analysts at Piper SandlerMay 13 at 5:10 PM | seekingalpha.comFate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call TranscriptMay 13 at 5:10 PM | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call TranscriptMay 12 at 4:58 AM | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) PT Lowered to $9.00May 12 at 2:53 AM | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Rating Lowered to Sell at StockNews.comMay 11 at 5:39 PM | marketbeat.comMonaco Asset Management SAM Acquires 335,284 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)Monaco Asset Management SAM increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 18.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,183,228 shares of the biopharmaceutical compaMay 11 at 12:09 PM | finance.yahoo.comFate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineMay 11 at 12:16 AM | marketbeat.comStockNews.com Downgrades Fate Therapeutics (NASDAQ:FATE) to SellStockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday.May 10, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Issues Quarterly Earnings Results, Hits ExpectationsFate Therapeutics (NASDAQ:FATE - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.47) EPS for the quarter, meeting analysts' consensus estimates of ($0.47). The business had revenue of $1.93 million for the quarter, compared to analysts' expectations of $0.80 million. Fate Therapeutics had a negative net margin of 253.30% and a negative return on equity of 38.17%. During the same period last year, the business earned ($0.19) earnings per share.May 10, 2024 | marketbeat.comCanaccord Genuity Group Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $9.00Canaccord Genuity Group reduced their price objective on Fate Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Friday.May 10, 2024 | markets.businessinsider.comFate Therapeutics: Strategic Shifts Prompt Hold Rating Amidst Awaited Clinical ResultsMay 10, 2024 | finance.yahoo.comFate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...May 9, 2024 | investorplace.comFATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | sfgate.comFate Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | msn.comFate Therapeutics GAAP EPS of -$0.47 in-line, revenue of $1.93M beats by $0.67MMay 9, 2024 | globenewswire.comFate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 9, 2024 | globenewswire.comFate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramMay 9, 2024 | americanbankingnews.comFate Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.42) Per Share (NASDAQ:FATE)May 8, 2024 | markets.businessinsider.comHere's what to expect from Fate Therapeutics's earningsMay 8, 2024 | msn.comFate Therapeutics Q1 2024 Earnings PreviewMay 8, 2024 | marketbeat.comFate Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.42) Per Share, Wedbush Forecasts (NASDAQ:FATE)Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Wedbush lifted their Q1 2024 earnings per share (EPS) estimates for Fate Therapeutics in a note issued to investors on Monday, May 6th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.42May 8, 2024 | americanbankingnews.comWedbush Reiterates "Neutral" Rating for Fate Therapeutics (NASDAQ:FATE)May 7, 2024 | marketbeat.comFate Therapeutics (FATE) Set to Announce Quarterly Earnings on ThursdayFate Therapeutics (NASDAQ:FATE) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 6, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Earns Neutral Rating from WedbushWedbush reaffirmed a "neutral" rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Monday.May 6, 2024 | finance.yahoo.comFate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesMay 3, 2024 | globenewswire.comFate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingMay 2, 2024 | finance.yahoo.comAskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024May 2, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)April 29, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Short Interest UpdateFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 18,920,000 shares, an increase of 14.7% from the March 31st total of 16,490,000 shares. Based on an average daily trading volume, of 2,780,000 shares, the short-interest ratio is currently 6.8 days.April 29, 2024 | seekingalpha.comFate Therapeutics: As Its Rally Fizzles, We May Be Near The BottomApril 27, 2024 | thestreet.comStruggling retail chain shares Chapter 11 bankruptcy fateApril 26, 2024 | msn.comGrandmother gets new lease on life from heart pump, pig kidneyApril 26, 2024 | msn.comBiden campaign says it will keep using TikTok - despite president signing law that could ban appApril 26, 2024 | yahoo.comOrlando police fulfill 4-year-old boy's dream of being an officerApril 25, 2024 | marketbeat.comFederated Hermes Inc. Sells 601,672 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)Federated Hermes Inc. lessened its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 24.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,849,872 shares of the biopharmaceutical company'April 23, 2024 | nytimes.comOur Reporter on the Fate of a Gazan University ClassApril 23, 2024 | marketbeat.comFate Therapeutics' (FATE) "Neutral" Rating Reaffirmed at WedbushWedbush reissued a "neutral" rating and issued a $7.00 target price on shares of Fate Therapeutics in a report on Tuesday.April 22, 2024 | globenewswire.comFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingApril 19, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Shares Down 5.4% Fate Therapeutics (NASDAQ:FATE) Shares Down 5.4%April 18, 2024 | msn.comFate Therapeutics files to sell 3.64M shares for holdersApril 17, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Shares Gap Up to $5.38Fate Therapeutics (NASDAQ:FATE) Shares Gap Up to $5.38April 15, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short InterestFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 16,490,000 shares, an increase of 25.3% from the March 15th total of 13,160,000 shares. Approximately 19.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,860,000 shares, the short-interest ratio is presently 5.8 days.April 14, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Position Trimmed by Vanguard Group Inc.Vanguard Group Inc. trimmed its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 7.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,908,351 shares of the biopharmaceutical company's stock after selliApril 11, 2024 | marketbeat.comFate Therapeutics' (FATE) Hold Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a research note on Thursday.April 10, 2024 | msn.comA promising target for new RNA therapeutics now accessibleApril 8, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock Price Down 2.5%Fate Therapeutics (NASDAQ:FATE) Shares Down 2.5%April 8, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 217,640 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)Assenagon Asset Management S.A. decreased its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 57.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,097 shares of the biopharmaceutical comApril 3, 2024 | yahoo.comTerminator: Edward Furlong Addresses John Connor’s Death In Dark FateApril 3, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock Price Up 7.1%Fate Therapeutics (NASDAQ:FATE) Stock Price Up 7.1% Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide FATE Media Mentions By Week FATE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.120.57▲Average Medical News Sentiment FATE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼313▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lexeo Therapeutics News iTeos Therapeutics News Alvotech News Adaptive Biotechnologies News Replimune Group News Taysha Gene Therapies News Editas Medicine News C4 Therapeutics News TScan Therapeutics News Voyager Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportGuard Against the Coming Financial UpheavalPorter & CompanyDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThis 1 Biotech Stock has been shocking the marketsHuge AlertsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
